Consensus Gilead Sciences, Inc.

Equities

GILD

US3755581036

Market Closed - Nasdaq 16:00:00 2024-05-28 EDT 5-day change 1st Jan Change
63.94 USD -2.65% Intraday chart for Gilead Sciences, Inc. -4.98% -21.07%

Evolution of the average Target Price on Gilead Sciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

96f066a333.aYhdLxWt64peBXX0uP1NxKW-X0SzgsqkLCAuluYcUuc.UNwzbX2U2dk3UhGW7qsp6cSOMxTw1rvAWXJG0JJKE9Mz_zMbdOaysh1kTQ~08c9243633df637b16bf82e1fcd68547
UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating MT
Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75 MT
Maxim Adjusts Price Target on Gilead Sciences to $85 From $90 MT
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $117 From $120 MT
Barclays Adjusts Price Target on Gilead Sciences to $76 From $80 MT
TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 MT
Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95 MT
RBC Capital Adjusts Gilead Sciences' Price Target to $74 From $76 MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $78 From $80 MT
North American Morning Briefing : More Tech -2- DJ
HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69 MT
Argus Cuts Price Target on Gilead Sciences to $75 From $85 MT
Cantor Fitzgerald Adjusts Gilead Sciences' Price Target to $75 From $78, Maintains Neutral Rating MT
BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89 MT
Leerink Partners Adjusts Gilead Sciences Price Target to $74 From $79 MT
UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating MT
Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76 MT
Morgan Stanley Cuts Price Target on Gilead Sciences to $80 From $83, Keeps Equalweight Rating MT
Wells Fargo Cuts Price Target on Gilead Sciences to $78 From $84, Keeps Equalweight Rating MT
Mizuho Securities Cuts Price Target on Gilead Sciences to $90 From $101, Maintains Buy Rating MT
Truist Securities Downgrades Gilead Sciences to Hold From Buy, Cuts Price Target to $82 From $91 MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia... Our Logo
RBC Trims Price Target on Gilead Sciences to $75 From $76, Keeps Sector Perform Rating MT
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy on Heels of Announced Sale to Gilead Sciences, Raises PT to $32.50 From $29 MT
Oppenheimer Cuts Gilead Sciences Price Target to $105 From $115, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.94 USD
Average target price
82.77 USD
Spread / Average Target
+29.46%
High Price Target
117 USD
Spread / Highest target
+82.98%
Low Price Target
67 USD
Spread / Lowest Target
+4.79%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Gilead Sciences, Inc.

UBS
Deutsche Bank Securities
Maxim
Redburn Atlantic
Barclays
TD Cowen
Jefferies & Co.
RBC Capital Markets
Morgan Stanley
HSBC
Argus
Cantor Fitzgerald
BMO Capital
Leerink Partners
Goldman Sachs
Wells Fargo Securities
Mizuho Securities
Truist Securities
Oppenheimer
Piper Sandler
BofA Securities
SVB Securities LLC
Cowen
JPMorgan Chase
SVB Leerink
Credit Suisse
Bernstein
Redburn
DZ BANK Elmar Kraus
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Consensus Gilead Sciences, Inc.